Holen Sie sich die Stockscreener-App
1.67
1.21%
0.02
Handel nachbörslich:
1.64
-0.03
-1.80%
Schlusskurs vom Vortag:
$1.65
Offen:
$1.68
24-Stunden-Volumen:
30,162
Relative Volume:
0.29
Marktkapitalisierung:
$20.87M
Einnahmen:
$10.16M
Nettoeinkommen (Verlust:
$-47.57M
KGV:
-0.2027
EPS:
-8.24
Netto-Cashflow:
$-42.73M
1W Leistung:
+4.37%
1M Leistung:
-9.24%
6M Leistung:
-46.47%
1J Leistung:
-74.03%
1-Tages-Spanne:
$1.64
$1.74
1-Wochen-Bereich:
$1.471
$1.78
52-Wochen-Spanne:
$1.02
$6.46
Curis Inc Stock (CRIS) Company Profile
Firmenname
Curis Inc
Sektor
Branche
Telefon
617-503-6500
Adresse
128 SPRING STREET, LEXINGTON, MA
Vergleichen Sie CRIS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.67 | 21.62M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2022-04-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-29 | Eingeleitet | Laidlaw | Buy |
| 2020-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-08-11 | Eingeleitet | FBR Capital | Outperform |
| 2015-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-21 | Bestätigt | ROTH Capital | Buy |
| 2014-05-09 | Bestätigt | Oppenheimer | Outperform |
| 2013-10-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2013-09-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2012-11-14 | Eingeleitet | Stifel Nicolaus | Hold |
| 2012-01-31 | Bestätigt | Brean Murray | Buy |
| 2012-01-31 | Bestätigt | Summer Street Research | Buy |
| 2011-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2011-10-06 | Eingeleitet | Summer Street Research | Buy |
| 2011-09-22 | Eingeleitet | MLV Capital | Buy |
| 2011-03-21 | Bestätigt | Brean Murray | Buy |
| 2010-02-26 | Bestätigt | Roth Capital | Buy |
| 2010-01-07 | Eingeleitet | Roth Capital | Buy |
Alle ansehen
Curis Inc Aktie (CRIS) Neueste Nachrichten
Curis Inc. Stock Approaches Key Moving AverageVolume Spike & AI Optimized Trade Strategies - thegnnews.com
Institutional Tools Highlight Unusual Flow in Curis Inc.July 2025 Macro Moves & AI Powered Trade Plan Recommendations - 선데이타임즈
Traders Consider Averaging Down in Curis Inc.2025 Volume Leaders & Advanced Swing Trade Entry Plans - metal.it
Bollinger Bands Show Potential Breakout in Curis Inc.July 2025 Outlook & Consistent Growth Equity Picks - 선데이타임즈
How Curis Inc. stock performs during market volatilityJuly 2025 Pullbacks & Weekly Setup with ROI Potential - 선데이타임즈
Can Curis Inc. continue delivering strong returnsJuly 2025 Breakouts & Technical Confirmation Trade Alerts - mustnews.co.kr
Market reaction to Curis Inc.’s recent newsAsset Safety Selection Using Quantitative Analysis - Newser
Exit strategy if you’re trapped in Curis Inc.Next Day Momentum Stock Forecasting Report - Newser
What makes Curis Inc. stock price move sharplyGiant Leap Stock Alerts - thegnnews.com
Curis Inc. Receives Buy Rating Due to Promising Clinical Developments and Strong Financial Position. - AInvest
Curis Files Prospectus Supplement for Stock Offering - MSN
Curis Inc. Receives Buy Rating Amid Promising Clinical Developments and Strong Financial Position - TipRanks
Curis targets enrolling 30–40 additional patients for NDA and EMA submissions as emavusertib studies advance - MSN
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target - simplywall.st
Curis, Inc. Analysts Trim Price Target After Q2 Report - AInvest
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Curis, Inc. Reports Q2 2025 Financial and Clinical Progress - The Globe and Mail
Curis 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth - AInvest
Curis, Inc. shares rise 1.74% intraday as Swiss president meets business leaders in Washington ahead of tariff talks. - AInvest
Curis Inc (CRIS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Curis Inc (CRIS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Curis, Inc. (NASDAQ:CRIS) Q2 2025 Earnings Call Transcript - Insider Monkey
Curis Provides Second Quarter 2025 Business Update - BioSpace
Curis: Q2 Earnings Snapshot - New Haven Register
Curis Inc. Earnings Call: Progress Amid Challenges - TipRanks
Curis Inc. Q2 Earnings Call Highlights: Progress Amid Challenges - AInvest
Curis (CRIS) Q2 Loss Narrows 66% - The Motley Fool
Curis Inc: Promising Financial Performance and Clinical Advancements Justify Buy Rating - TipRanks
Earnings call transcript: Curis Inc’s Q2 2025 sees reduced losses, stock rises - Investing.com
Earnings call transcript: Curis Inc’s Q2 2025 sees reduced losses, stock rises By Investing.com - Investing.com South Africa
Curis Inc: A High-Conviction Biotech Play with Accelerating Catalysts in Hematology - AInvest
Curis, Inc. Q2 2025: Unraveling Contradictions in Enrollment Strategy, FDA Dynamics, and PCNSL Data Expectations - AInvest
Transcript : Curis, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Curis Inc (CRIS) Q2 2025 Earnings: EPS of -$0.68 Beats Estimate, Revenue Hits $2.7 Million - GuruFocus
Biotech firm Curis Q2 revenue rises to $2.7 mln - MarketScreener
Curis Inc (CRIS) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
How strong is Curis Inc. company’s balance sheetTrack top-performing stocks effortlessly - Jammu Links News
What are the technical indicators suggesting about Curis Inc.Exceptional gains - Jammu Links News
Curis Inc Q2 2025 Earnings Report Preview: Revenue Expected to Reach $2.64 Million, Earnings at -$1.36 per Share - AInvest
What catalysts could drive Curis Inc. stock higher in 2025Achieve breakthrough investment performance - Jammu Links News
How does Curis Inc. compare to its industry peersGet real-time updates on market trends - Jammu Links News
What drives Curis Inc. stock priceUnmatched market gains - Jammu Links News
What are Curis Inc. company’s key revenue driversInvest smarter with daily trading signals - Jammu Links News
What are analysts’ price targets for Curis Inc. in the next 12 monthsTurn volatility into profit opportunities - Jammu Links News
What is Curis Inc. company’s growth strategyBreakthrough financial growth - Jammu Links News
Finanzdaten der Curis Inc-Aktie (CRIS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):